One of the main challenges in the development and use of immunotoxins is immunogenicity. The human immune system may recognize the foreign protein components of the immunotoxin as threats, leading to the production of antibodies that neutralize its effects. Additionally, the heterogeneous expression of target antigens on cancer cells can affect the efficacy of the treatment. Off-target effects and the potential for severe side effects also pose significant challenges.
